Fas ligand gene transfer effectively induces apoptosis in head and neck cancer cells

Acta Oto-Laryngologica

Volumn 131, Issue 8, 2011, Pages 876-881

  Ji, Xiaojun ^a   Jiang, Chen ^a   Liu, Yuhe ^a   Bu, Dingfang ^a   Xiao, Shuifang ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Acid ceramidase; Fas FasL; Green fluorescent protein

Indexed keywords

ACID CERAMIDASE; EPIDERMAL GROWTH FACTOR; FAS LIGAND; GREEN FLUORESCENT PROTEIN;

APOPTOSIS; ARTICLE; ASSAY; CANCER CELL; CELL DEATH; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE IMAGING; GENETIC TRANSFECTION; HEAD AND NECK CANCER; HEP 2 CELL; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; THERAPY EFFECT;

ACID CERAMIDASE; APOPTOSIS; CELL LINE, TUMOR; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEAD AND NECK NEOPLASMS; HUMANS; MICROSCOPY, FLUORESCENCE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY;

EID: 79960451414     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.3109/00016489.2011.562539     Document Type: Article

References (20)

1. Zhang L, Fang B. Mechanisms of resistance to TRAILinduced apoptosis in cancer. Cancer Gene Ther 2005;12: 228-37. (Pubitemid 40315182)
2. Sudarshan S, Holman DH, Hyer ML, Voelkel Johnson C, Dong JY, Norris JS. In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. Cancer Gene Therapy 2005;12:12-18. (Pubitemid 39665238)
3. Norris JS, Bielawska A, Day T, El-Zawahri A, ElOjeimy S, Hannun Y, et al. Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther 2006;13:1045-51. (Pubitemid 44760102)
4. Musumarra G, Barresi V, Condorelli DF, Scire S. A bioinformatic approach to the identification of candidate genes for the development of new cancer diagnostics. Biol Chem 2003;384:321-7. (Pubitemid 36348334)
5. Seelan RS, Qian C, Yokomizo A, Bostwick DG, Smith DI, Liu W. Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes Chromosomes Cancer 2000;29:137-46.
6. Brunner T, Wasem C, Torgler R, Cima I, Jakob S, Corazza N. Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology. Semin Immunol 2003;15:67-76.
7. Houston A, OConnell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 2004;4:321-6. (Pubitemid 38987056)
8. SeinoK, KayagakiN, Okumura K, YagitaH. Antitumor effect of locally produced CD95 ligand. Nat Med 1997;3:165-70. (Pubitemid 27064700)
9. Zheng SY, Li DC, Zhang ZD, Zhao J, Ge JF. Adenovirusmediated FasL gene transfer into human gastric carcinoma. World J Gastroenterol 2005;11:3446-50. (Pubitemid 40873252)
10. Ambar BB, Frei K, Malipiero U, Morelli AE, Castro MG, Lowenstein PR, et al. Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. Hum Gene Ther 1999;10:1641-8. (Pubitemid 29328208)
11. Li X, Liu YH, Zhang YP, Zhang S, Pu X, Gardner TA, et al. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy. Clin Cancer Res 2007;13(18 Pt 1):463-73.
12. Bernier J, Cooper JS. Chemoradiation after surgery for high risk head and neck cancer patients: how strong is the evidence? Oncologist 2005;10:215-24. (Pubitemid 40463159)
13. Friesen C, Fulda S, Debatin KM. Cytotoxic drugs and the CD95 pathway. Leukemia 1999;13:1854-8. (Pubitemid 29535271)
14. Hyer ML, Sudarshan S, Schwartz DA, Hannun YA, Dong J-Y, Norris JS. Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression. Cancer Gene Ther 2003;10:330-9. (Pubitemid 36423115)
15. ElOjeimy S, McKillop JC, El-Zawahry AM, Holman DH, Liu X, Schwartz DA, et al. FasL gene therapy: a new therapeutic modality for head and neck cancer. Cancer Gene Ther 2006;13:739-45. (Pubitemid 44100486)
16. OConnell J, Bennett MW, Nally K, Houston A, OSullivan GC, Shanahan F. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict. Ann N Y Acad Sci 2000;910: 178-92; discussion 193-5.
17. Li W, Zhang C, Chen C, Zhuang G. Correlation between expression of DcR3 on tumor cells and sensitivity to FasL. Cell Mol Immunol 2007;4:455-60.
18. Strelow A, Bernardo K, Adam-Klages S, Linke T, Sandhoff K, Krönke M, et al. Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death. J Exp Med 2000;192:601-12.
19. Saad AF, Meacham WD, Bai A, Anelli V, Elojeimy S, Mahdy AE, et al. The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther 2007;6:1455-60. (Pubitemid 351590358)
20. Elojeimy S, Liu X, McKillop JC, El-Zawahry AM, Holman DH, Cheng JY, et al. Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy. Mol Ther 2007;15:1259-63. (Pubitemid 46965321)